Q-omics provides the consensus-scored GCNT1P3 profile across patient tissues and cancer cell-line models. GCNT1P3 expression is associated with patient survival in 18 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GCNT1P3 is differentially expressed in 10, with the highest sampling consensus in KIRC. Additionally, GCNT1P3 RNA expression shows 9,151 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight KIRC, and LSCC as cancer lineages where GCNT1P3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GCNT1P3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GCNT1P3 survival associations across molecular data types. GCNT1P3 RNA expression shows survival associations in the most cancer types (18). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GCNT1P3 RNA expression–survival associations across cancer types. High GCNT1P3 expression shows unfavorable associations in KIRC, MESO, LGG and THCA, but favorable associations in ESCA and LUAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .003). Together, the overview and detailed table identify KIRC as the clearest survival context for GCNT1P3 RNA expression.
This table summarizes GCNT1P3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for GCNT1P3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GCNT1P3 shows lower tumor expression in LIHC and higher tumor expression in KIRC, HNSC, THCA, LUSC and BRCA. The KIRC box plot shows higher GCNT1P3 RNA expression in tumor versus normal tissue (log2 FC = +0.071, t-test p < 0.001).
This table shows molecular features associated with GCNT1P3 in patient tissues and cancer cell lines. In patient samples, GCNT1P3 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
